Docetaxel, when used with or without prednisone, was the first chemotherapy drug proven to help patients live longer with advanced prostate cancer. The average survival was improved by about two-and-a-half months when compared to mitoxantrone with or without prednisone. Docetaxel has the best results when given every three weeks as compared to weekly dosing. Cabazitaxel (Jevtana) is another chemotherapy drug, used in combination with the steroid prednisone, to treat men with prostate cancer. Cabazitaxel (Jevtana) is used in men with advanced prostate cancer that has progressed during, or after, treatment with docetaxel (Taxotere).